By far the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompany it with periodic exacerbations. Drug therapy is an important component in the general structure of the treatment of prostate diseases. In addition, treatment often ends in defeat due to improper therapy, missed medications and, when the condition is alleviated, ignoring the disease.
Thus, 20-30% of patients are not satisfied with the treatment, do not feel a decrease in the symptoms of urinary disorders and an improvement in the quality of life. Most likely, this is due to an incorrect assessment of the function of the lower urinary tract in men with BPH and, accordingly, the choice of inadequate treatment.
As you know, prostatitis is acute and chronic (CP), bacterial and abacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic abacterial prostatitis - 80–90%, including prostatodynia - 20–30%.
The most common is chronic abacterial prostatitis, which must be controlled and timely prevented exacerbations with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5a-reductase inhibitors (finasteride, dutasteride);
- a-blockers (doxazosin, tamsulosin);
- phytotherapy (sabal palm extract);
- antibiotics;
- amino acid complexes;
- animal organ extracts (prostate extract);
- entomotherapy drugs (products derived from insects).
At the same time, in 13-30% of the effect from the use of a-blockers does not occur within 3 months of treatment - further therapy with drugs of this group is not advisable.
When prescribing finasteride, the doctor needs to be prepared for the fact that the most significant side effects of the drug: impotence, decreased libido, decrease in ejaculate volume can lead to self-withdrawal of the drug by the patient.
Treatment of BPH and prostatitis is an important, not fully resolved urological problem.
Frequent exacerbations of CP in the absence of indications for surgery on the prostate gland force the doctor to use additional methods in drug treatment. Often, the presence of concomitant CP aggravates the course of BPH, becauseinflammation in 80% of cases is in the prostate gland with benign hyperplasia.
Modern medicine gives us new opportunities for the treatment of CP and BPH and the prevention of exacerbations.